Literature DB >> 30094412

Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in KIT-Mutant Melanoma.

Junna Oba1, Sun-Hee Kim1, Wei-Lien Wang1, Mariana P Macedo1, Fernando Carapeto1, Meredith A McKean1, John Van Arnam1, Agda K Eterovic1, Shiraj Sen1, Charuta R Kale1, Xiaoxing Yu1, Cara L Haymaker1, Mark Routbort1, Lauren E Haydu1, Chantale Bernatchez1, Alexander J Lazar1, Elizabeth A Grimm1, David S Hong1, Scott E Woodman1.   

Abstract

Entities:  

Year:  2018        PMID： 30094412      PMCID： PMC6080631          DOI： 10.1200/PO.18.00055

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  31 in total

Review 1.  Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics.

Authors:  Scott E Woodman; Michael A Davies
Journal:  Biochem Pharmacol       Date:  2010-05-08       Impact factor: 5.858

2.  Distinct sets of genetic alterations in melanoma.

Authors:  John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

3.  KIT as a therapeutic target in metastatic melanoma.

Authors:  Richard D Carvajal; Cristina R Antonescu; Jedd D Wolchok; Paul B Chapman; Ruth-Ann Roman; Jerrold Teitcher; Katherine S Panageas; Klaus J Busam; Bartosz Chmielowski; Jose Lutzky; Anna C Pavlick; Anne Fusco; Lauren Cane; Naoko Takebe; Swapna Vemula; Nancy Bouvier; Boris C Bastian; Gary K Schwartz
Journal:  JAMA       Date:  2011-06-08       Impact factor: 56.272

4.  Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.

Authors:  Cristina R Antonescu; Peter Besmer; Tianhua Guo; Knarik Arkun; Glory Hom; Beata Koryotowski; Margaret A Leversha; Philip D Jeffrey; Diann Desantis; Samuel Singer; Murray F Brennan; Robert G Maki; Ronald P DeMatteo
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

5.  The phosphatidyl inositol 3-kinase pathway is central to the pathogenesis of Kit-activated melanoma.

Authors:  Ruixia Liang; Andrea R Wallace; Dirk Schadendorf; Brian P Rubin
Journal:  Pigment Cell Melanoma Res       Date:  2011-06-10       Impact factor: 4.693

6.  The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma.

Authors:  J R Todd; L L Scurr; T M Becker; R F Kefford; H Rizos
Journal:  Oncogene       Date:  2012-12-17       Impact factor: 9.867

7.  KIT gene mutations and copy number in melanoma subtypes.

Authors:  Carol Beadling; Erick Jacobson-Dunlop; F Stephen Hodi; Claudia Le; Andrea Warrick; Janice Patterson; Ajia Town; Amy Harlow; Frank Cruz; Sharl Azar; Brian P Rubin; Susan Muller; Rob West; Michael C Heinrich; Christopher L Corless
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

8.  Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.

Authors:  Scott E Woodman; Jonathan C Trent; Katherine Stemke-Hale; Alexander J Lazar; Sabrina Pricl; Giovanni M Pavan; Maurizio Fermeglia; Y N Vashisht Gopal; Dan Yang; Donald A Podoloff; Doina Ivan; Kevin B Kim; Nicholas Papadopoulos; Patrick Hwu; Gordon B Mills; Michael A Davies
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

9.  Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06).

Authors:  Su Jin Lee; Tae Min Kim; Yu Jung Kim; Kee-Taek Jang; Hyo Jin Lee; Soon Nam Lee; Mi Sun Ahn; In Gyu Hwang; Suee Lee; Moon-Hee Lee; Jeeyun Lee
Journal:  Oncologist       Date:  2015-09-30

10.  Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.

Authors:  Erika von Euw; Mohammad Atefi; Narsis Attar; Connie Chu; Sybil Zachariah; Barry L Burgess; Stephen Mok; Charles Ng; Deborah Jl Wong; Bartosz Chmielowski; David I Lichter; Richard C Koya; Tara A McCannel; Elena Izmailova; Antoni Ribas
Journal:  Mol Cancer       Date:  2012-04-19       Impact factor: 27.401
View more
  6 in total

Review 1.  Potential Biomarkers of Skin Melanoma Resistance to Targeted Therapy-Present State and Perspectives.

Authors:  Magdalena Olbryt
Journal:  Cancers (Basel)       Date:  2022-05-06       Impact factor: 6.575

Review 2.  Targeted Therapy and Immunotherapy for Melanoma in Japan.

Authors:  Kenjiro Namikawa; Naoya Yamazaki
Journal:  Curr Treat Options Oncol       Date:  2019-01-24

3.  FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma.

Authors:  Pauline Tétu; Julie Delyon; Jocelyne André; Coralie Reger de Moura; Malak Sabbah; Ghanem E Ghanem; Maxime Battistella; Samia Mourah; Céleste Lebbé; Nicolas Dumaz
Journal:  Cancers (Basel)       Date:  2020-04-25       Impact factor: 6.639

4.  Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes.

Authors:  Robert A Szczepaniak Sloane; Michael G White; Russell G Witt; Anik Banerjee; Michael A Davies; Guangchun Han; Elizabeth Burton; Nadim Ajami; Julie M Simon; Chantale Bernatchez; Lauren E Haydu; Hussein A Tawbi; Jeffrey E Gershenwald; Emily Keung; Merrick Ross; Jennifer McQuade; Rodabe N Amaria; Khalida Wani; Alexander J Lazar; Scott E Woodman; Linghua Wang; Miles C Andrews; Jennifer A Wargo
Journal:  Cancers (Basel)       Date:  2021-10-22       Impact factor: 6.639

5.  Multi-modal molecular programs regulate melanoma cell state.

Authors:  Miles C Andrews; Junna Oba; Chang-Jiun Wu; Haifeng Zhu; Tatiana Karpinets; Caitlin A Creasy; Marie-Andrée Forget; Xiaoxing Yu; Xingzhi Song; Xizeng Mao; A Gordon Robertson; Gabriele Romano; Peng Li; Elizabeth M Burton; Yiling Lu; Robert Szczepaniak Sloane; Khalida M Wani; Kunal Rai; Alexander J Lazar; Lauren E Haydu; Matias A Bustos; Jianjun Shen; Yueping Chen; Margaret B Morgan; Jennifer A Wargo; Lawrence N Kwong; Cara L Haymaker; Elizabeth A Grimm; Patrick Hwu; Dave S B Hoon; Jianhua Zhang; Jeffrey E Gershenwald; Michael A Davies; P Andrew Futreal; Chantale Bernatchez; Scott E Woodman
Journal:  Nat Commun       Date:  2022-07-09       Impact factor: 17.694

6.  Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy.

Authors:  Christopher J Terranova; Ming Tang; Mayinuer Maitituoheti; Ayush T Raman; Archit K Ghosh; Jonathan Schulz; Samir B Amin; Elias Orouji; Katarzyna Tomczak; Sharmistha Sarkar; Junna Oba; Caitlin Creasy; Chang-Jiun Wu; Samia Khan; Rossana Lazcano; Khalida Wani; Anand Singh; Praveen Barrodia; Dongyu Zhao; Kaifu Chen; Lauren E Haydu; Wei-Lien Wang; Alexander J Lazar; Scott E Woodman; Chantale Bernatchez; Kunal Rai
Journal:  Cell Rep       Date:  2021-07-20       Impact factor: 9.423
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.